Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study

References

• Gasparetto C. Stem cell transplantation for multiple myeloma. Cancer Control 2004; 11: 119–129
   PubMedGoogle Scholar
• Barlogie B, Tricot G J, Van R F, Angtuaco E, Walker R, Epstein J, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164
   PubMed Web of Science ®Google Scholar
• Qazilbash M H, Saliba R M, Aleman A, Lei X, Weber D, Carrasco A, et al. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 2006; 47: 1360–1364
   PubMed Web of Science ®Google Scholar
• Davies F E, Rawstron A C, Owen R G, Morgan G J. Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol 2002; 15: 197–222
   PubMed Web of Science ®Google Scholar
• Lahuerta J J, Martinez-Lopez J, Serna J D, Blade J, Grande C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438–446
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Alvares C L, Davies F E, Horton C, Patel G, Powles R, Sirohi B, et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 2005; 129: 607–614
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Attal M, Divine M, Marit G, Leblond V, Stoppa A M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077–3085
   PubMed Web of Science ®Google Scholar
• O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731–737
   PubMed Web of Science ®Google Scholar
• Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L, et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159–164
   PubMed Web of Science ®Google Scholar
• Davies F E, Forsyth P D, Rawstron A C, Owen R G, Pratt G, Evans P A, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112: 814–819
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Fonseca R, Dispenzieri A, Lacy M Q, Witzig T E, Lust J A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26: 979–983
   PubMed Web of Science ®Google Scholar
• Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, et al. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211–217
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Fonseca R, Dispenzieri A, Lacy M Q, Lust J A, Witzig T E, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001; 68: 269–275
   PubMed Web of Science ®Google Scholar
• Zent C S, Wilson C S, Tricot G, Jagannath S, Siegel D, Desikan K R, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998; 91: 3518–3523
   PubMed Web of Science ®Google Scholar
• Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero M D, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999; 107: 121–131
   PubMed Web of Science ®Google Scholar
• Harada H, Kawano M M, Huang N, Harada Y, Iwato K, Tanabe O, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658–2663
   PubMed Web of Science ®Google Scholar
• Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Hematol 2002; 117: 882–885
   PubMed Web of Science ®Google Scholar
• Rawstron A C, Fenton J AL, Ashcroft J, English A, Jones R A, Richards S J, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000; 96: 3880–3886
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Gutierrez N C, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer 2006; 42: 1510–1519
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002; 99: 1853–1856
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Vidriales M B, Mateo G, Garcia-Sanz R, Mateos M V, Garcia de C A, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering mutliple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586–9252
   PubMed Web of Science ®Google Scholar
• Mateo M G, San M I, Orfao de M A. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005; 113: 5–24
   PubMedGoogle Scholar
• Rawstron A C, Davies F E, DasGupta R, Ashcroft A J, Patmore R, Drayson M T, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100: 3095–3100
   PubMed Web of Science ®Google Scholar
• Durie B G, Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Cogle C R, Moreb J S, Leather H L, Finiewicz K J, Khan S A, Reddy V S, et al. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am J Hematol 2003; 73: 169–175
   PubMed Web of Science ®Google Scholar
• Ng A P, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 2006; 91: 972–975
   PubMed Web of Science ®Google Scholar
• Zhao X, Huang Q, Slovak M, Weiss L. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol 2006; 125: 895–904
   PubMed Web of Science ®Google Scholar
• Nadav L, Katz B Z, Baron S, Yossipov L, Polliack A, Deutsch V, et al. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol 2006; 133: 530–532
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, Wilson C S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482–488
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Bataille R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 2004; 32: 293–301
   PubMed Web of Science ®Google Scholar
• Schneider U, van L A, Huhn D, Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol 1997; 97: 56–64
   PubMed Web of Science ®Google Scholar
• Moreau P, Robillard N, vet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89: 547–551
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar S V, Kimlinger T, Greipp P R, Witzig T E. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 2005; 19: 1466–1470
   PubMed Web of Science ®Google Scholar
• Vogel W, Kopp H G, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 2005; 131: 214–218
   PubMed Web of Science ®Google Scholar
• Wei A, Westerman D, Feleppa F, Trivett M, Juneja S. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica 2005; 90: 1147–1148
   PubMed Web of Science ®Google Scholar
• Owen R G, Johnson R J, Rawstron A C, Evans P A, Jack A, Smith G M, et al. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol 1996; 49: 672–675
   PubMed Web of Science ®Google Scholar